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Internalization and degradation of filamentous bacteriophage M13 by a specific target cell may have major consequences
for the recovery of phage in in vivo biopanning of phage libraries. Therefore, we investigated the pharmacokinetics and
processing of native and receptor-targeted phage in mice. 35S-radiolabeled M13 was chemically modified by conjugation of
either galactose (lacM13) or succinic acid groups (sucM13) to the coat protein of the phage to stimulate uptake by galactose
recognizing hepatic receptors and scavenger receptors, respectively. Receptor-mediated endocytosis of modified phage
reduced the plasma half-life of native M13 (t1/2  4.5 h) to 18 min for lactosylated and 1.5 min for succinylated bacterophage.
Internalization of sucM13 was complete within 30 min after injection and resulted in up to 5000-fold reduction of bioactive
phage within 90 min. In conclusion, these data provide information on the in vivo behavior of wild-type and receptor-targeted
M13, which has important implications for future in vivo phage display experiments and for the potential use of M13 as a viralis; genINTRODUCTION
The development of phage display technology has
considerably facilitated the design of specific peptide
ligands or antibody fragments that bind to receptors and
target proteins, the majority of selections being per-
formed in vitro against immobilized antigens or cells
(Scott and Smith, 1990). In addition, in vivo biopanning
proved to be successful in the identification of organ-
specific ligands (Pasqualini and Ruoslahti, 1996). Illus-
tratively, in vivo phage display has been used to isolate
peptides which target tumor blood vessels and which
could be used to enhance the efficacy of the anticancer
drug doxorubicin against human breast cancer xeno-
grafts in mice (Arap et al., 1998). Other groups have
exploited in vivo biopanning to identify homing devices
for atherosclerosis in low density Lipoprotein-receptor
(LDLr) knockout mice (Houston et al., 2001), tracheal
tumors (Kennel et al., 2000), thymic endothelium (Johns et
al., 2000), and several other organs (Rajotte et al., 1998).
In these studies, however, the fate of phage in vivo has
not been quantitatively assessed, and selection was only
restricted to endothelial targets. We hypothesized that
internalization and degradation of phage after receptor
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182binding may significantly affect its recovery in vivo. The
ability of phage to be internalized was first shown for
phage displaying the Arg-Gly-ASP (RGD) motif (Hart et
al., 1994). This observation was exploited to enhance the
stringency of selection in phage display protocols and to
screen for ligands that confer efficient uptake by a spe-
cific cell type (Barry et al., 1996; Ivanenkov et al., 1999a;
Becerril et al., 1999). Internalizing phage were selected
against tumors (Poul et al., 2000), Epidermal Growth
Factor (EGF) receptor (Heitner et al., 2001), and even
phage with transcytotic capacity have been recovered
(Ivanenkov and Menon, 2000). Interestingly, Larocca et
al. have used internalizing phage to establish GFP and
-Gal expression in mammalian cells (Larocca et al.,
1999, 1998; Kassner et al., 1999). Recently, Giovine et al.
showed DNA transfection of phage via integrins (Giovine
et al., 2001). After uptake, the internalized phage enter
endosomal compartments (Ivanenkov et al., 1999b). Their
recovery could be significantly improved by the lysoso-
motropic agent chloroquine, suggesting that internalized
phage are indeed efficiently degraded upon uptake. The
processing and potential degradation of phage after re-
ceptor-mediated internalization by a specific receptor
may have major consequences for the recovery of phage
in selection protocols in vivo. Therefore, it is essential to
have detailed information on the in vivo fate of nativegene delivery vehicle. © 2002 Elsevier Science (USA)
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phage and of specific phages with high affinity for a
well-established internalizing receptor, measuring total
amount of tissue-associated phage particles rather than
colony forming units (infectious phage).
In the present study, M13 were metabolically labeled
with [35S]methionine/cysteine to quantitatively assess
the pharmacokinetics of native and targeted phage par-
ticles. As a model of a selected, receptor-specific phage
clone, phage were chemically modified by reductive lac-
tosamination (lacM13) or succinylation (sucM13) to stim-
ulate uptake by hepatic galactose receptors or by scav-
enger receptors on endothelial cells and macrophages,
respectively. We show that 35S-radiolabeled phage-tar-
geting galactose or scavenger receptors are more rap-
idly and specifically taken up in vivo by the liver than
nonmodified phage, making these chemical modifica-
tions not only representative tools for in vivo kinetic
studies, but also interesting for the use of bacteriophage
M13 as a gene delivery vehicle. Moreover, we demon-
strate that internalized phage are rapidly inactivated after
tissue uptake and provide evidence for possible extrav-
asation of the phage into subendothelial tissue, which
has implications for the phage display selection proto-
cols in vivo.
RESULTS
Serum decay and tissue distribution of bacteriophage
M13
First, the tissue distribution and serum clearance of
unmodified M13 were investigated. C57Bl/6KH were in-
jected with 35S-labeled M13 and the plasma recovery of
35S-radioactivity and colony forming units (CFU) was de-
termined at the indicated time points (Fig. 1A). After 30
min, mice were perfused with DMEM through the right
ventricle of the heart to remove nonbound phage. The
biodistribution (Fig. 1B) and specific biodistribution (per
gram tissue, Fig. 1C) of 35S-radioactivity and CFU were
determined in the indicated organs as a percentage of
the injected dose (%ID). Total recoveries of the organs
and plasma as indicated in Fig. 1B were 98 and 102% for
35S-radioactivity and CFU, respectively. The recovery of
CFU in plasma, heart, and kidney correlated well with
that of radioactivity. However, the recovery of CFU in
liver, spleen, and lungs was found to be consistently
lower than that of radioactivity in the same organ. As this
was not the case for kidney and heart, and as CFU
recovery in all organs were essentially 100% at 5 min
postinjection (data not shown), it is unlikely that the low
recovery of CFUs is owing to a loss of CFUs during the
isolation procedure. Rather, the difference between
CFUs and 35S-radioactivity for liver, lungs, and spleen at
30 min after injection may be caused by lysosomal deg-
radation of the phages after uptake by the target tissue.
Comparable results were obtained for 129/ICR white
mice. In these mice, the half-life of naked M13 was
approximately 4 h. Uptake of 35S-M13 was largest in liver
(4.7% of ID) and spleen (0.8% of ID). Recovery of CFUs as
compared to radiolabeled M13 was 50–80% lower for
lungs, liver, and spleen, but identical for heart and kidney
(not shown). This shows that the results obtained are not
specific to one inbred strain of mice.
Serum decay and tissue distribution of succinylated
and lactosylated M13
The above results show that bacteriophage M13 is
cleared very slowly from the circulation. As a measure of
a selected phage with affinity for a specific internalizing
receptor, 35S-M13 was chemically modified with lactose
or succinic anhydride to induce receptor-mediated up-
take by the hepatic galactose receptors and scavenger
FIG. 1. In vivo fate of M13 phage in mice: Recovery of 35S-radioactivity
and colony forming units (CFU). Mice were injected with 35S-M13 (1010
CFU in 200 l PBS). The 35S-radioactivity (f) and CFUs (Œ) in serum
were determined at the indicated timepoints (A). After 30 min, the mice
were perfused with DMEM, the organs homogenised, and assayed for
35S and CFU. Values are expressed as percentage of injected dose (B)
or as percentage of injected dose per gram tissue (C). Open bars, 35S
(total recovery 98%); hatched bars, CFU (total recovery 102%). Values
represent means  variation of duplicate experiments.
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receptors, respectively. To exclude that the chemical
modifications led to aggregation or disintegration of the
bacteriophage, 35S-lacM13 and 35S-sucM13 were sub-
jected to size exclusion (SE) chromatography on a
Sephacryl S1000 column and the eluted fractions were
assayed for radioactivity (Fig. 2A) and CFUs (Fig. 2B). The
elution profiles of lacM13 and sucM13 correlated well
with that of control M13, giving a broad peak at V elution 
1.3 ml. Recoveries were 95%. Furthermore, the phage
remained fully infective after the lactosylation and suc-
cinylation procedure, indicating that the chemical modi-
fications did not affect the integrity of the virus.
To show the effect of the galactose and succinyl group
on the in vivo behavior of the phage, mice were injected
with 35S-labeled sucM13 or lacM13 and both plasma
clearance and biodistribution profile were determined.
Figure 3A shows that the modifications led to an in-
creased plasma clearance. The plasma half-life of M13
(4.5 h) was reduced to 18 and 1.5 min for lacM13 and
sucM13, respectively. The rapid plasma clearance of
sucM13 and lacM13 phage was accompanied by a
changed biodistribution profile (Figs. 3B and 3C). The
major uptake site of sucM13 at 30 min after injection
(determined as a percentage of the injected dose, Fig.
3B), appeared to be liver (72  7%) and spleen (5.7 
0.9%), whereas lacM13 was taken up mainly by the liver
(50  1%). Uptake in the other organs was essentially
similar to that of unmodified M13. Figure 3C shows the
relatively large contribution of the spleen to the uptake of
sucM13 (82  5% per gram tissue) but not for lacM13
(7.5  0.2%). Furthermore, a difference in recovery be-
tween the CFUs and 35S-radioactivity was observed in
the target organs at 30 min after injection. The recovery
of CFUs as compared to 35S-radioactivity (%ID) were only
26.6% (liver) and 42.6% (spleen) for sucM13 and 54.7%
(liver) for lacM13 (not shown), suggesting that degrada-
tion of phage occurs as rapid as 30 min after injection.
The results shown in Fig. 3 have also been conducted in
129/ICR white mice with essentially similar results, indi-
FIG. 3. Effects of lactosylation and succinylation of M13 on the
plasma clearance and tissue distribution. Mice were injected with
35S-M13 (M13, ●), lactosylated 35S-M13 (lacM13, Œ), or succinylated
35S-M13 (sucM13, f) at 1010 CFU. At the indicated time points, 35S-
radioactivity in serum was determined (A). After 30 min, the mice were
perfused with DMEM and the recovery of 35S-radioactivity in the indi-
cated organs was determined and is expressed as percentage of the
injected dose (B) or as percentage of injected dose per gram tissue (C).
Open bars, M13 (total recovery 98%); hatched bars, lacM13 (total
recovery 96%); filled bars, sucM13 (total recovery 78%). Values repre-
sent means  variation of duplicate experiments.
FIG. 2. Chromatographic profiles of M13 (●), lacM13 (Œ), and sucM13
(f). Samples were injected onto a Sephacryl S-1000 SF column and
fractions were assayed for CFU (A) or 35S-radioactivity (B). CFU and 35S
values are expressed as percentage of injected amount (recoveries
were 95%).
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cating that the effects observed are not related to one
inbred strain of mice.
Uptake of lacM13 by liver cells
As demonstrated in the previous section, lacM13 is
taken up solely by the liver. Hepatic uptake of lactosy-
lated particles can be mediated by the asialoglycopro-
tein receptor (ASGPr) on parenchymal cells and the ga-
lactose particle receptor (GPr) on Kupffer cells. As the
GPr predominantly recognizes larger galactose-expos-
ing particles (15 nm) (Bijsterbosch and Van Berkel,
1990; Biessen et al., 1996), it is expected that the rod-like
lactosylated M13 (6  500 nm) is mainly targeted to the
Kupffer cells. Moreover, parenchymal cells are subendo-
thelial liver cells, shielded by endothelium-containing
feneastrae of approximately 100 nm (Wisse et al., 1985)
and thus supposedly inaccessible from the bloodstream
for M13 phage. To confirm this, we determined the rela-
tive contribution of parenchymal liver cells (PC) and non-
parenchymal cells (endothelial and Kupffer cells, NPC) to
the hepatic uptake of lacM13. Mice were injected with
35S-lacM13; after 20 min, the liver was perfused, and the
PCs and NPCs were isolated (95% purity, contamina-
tion of NPC in PC fraction  1%) and assayed for CFU
and 35S-radioactivity (Fig. 4). Indeed, the hepatic uptake
of lacM13 could be mainly attributed to NPCs (92  4%
of the total liver uptake of 35S). However, despite the low
accessibility of the PCs, still 8  3% of the injected dose
could be recovered from the PCs. CFU values of the in
vivo PC uptake (as a percentage of total CFU recovered)
correlated well with 35S-radioactivity, excluding that
mainly phage degradation products were recovered from
PCs. To check whether PCs are capable of taking up
lacM13, binding and internalization of lacM13 was stud-
ied in vitro on isolated parenchymal cells by incubating
the cells with lacM13 for 2 h at 37°C. Extracellular phage
were removed by proteinase K and the remaining CFUs
were determined (Fig. 5). Binding and uptake of lactosy-
lated phage at 37°C occurred in a Ca2-dependent fash-
ion (not shown). Uptake of nonlactosylated library phage
at 37°C and of lacM13 at 4°C was 1000 times reduced
(Fig. 5), establishing the essential role of galactose in the
recognition of the PC. These data suggest that lacM13 is
capable of passing the fenestrae and is specifically in-
ternalized by the ASGPr, albeit at a low efficacy. Inacti-
vation of CFUs was also seen in vitro when lacM13 was
recovered at different time points. The amount of lacM13
recovered after 6 h of incubation with isolated PCs was
only 5% as compared to the amount recovered after 1 h.
In the presence of chloroquine (an inhibitor of lysosomal
degradation) recovery was 25%, showing that degrada-
tion was also present in isolated PCs and that degrada-
tion could be decreased by a factor of 5 in the presence
of chloroquine.
Uptake and degradation of sucM13
It was shown above that succinylated M13 was rapidly
cleared from the circulation (t 1/ 2  1.5 min) and that the
major uptake sites of sucM13 at 30 min after injection
were liver (72  7%) and spleen (5.7  0.9%) (Figs. 3A
and 3B). Succinylated HSA is solely taken up by scaven-
ger receptors, mainly Scavenger Receptor A (SR-A), on
liver and spleen macrophages and endothelial cells
(Jansen et al., 1993a). To confirm receptor specificity of
sucM13, succinylated human serum albumin (sucHSA)
was injected at a dose of 40 mg/kg 1 min prior to the
injection of sucM13. SucHSA reduced the uptake of
FIG. 5. Uptake of lactosylated M13 by isolated mouse parenchymal
cells. Freshly isolated mouse parenchymal cells (1.106) were incubated
for 2 h at 37°C in 500 l DMEM/2%BSA in the presence of lactosylated
M13 (lacM13, 37°C) or native M13 (M13, 37°C) at a concentration of 107
CFU/l. LacM13 was also incubated at 4°C (lacM13, 4°C) to inhibit
ATP-driven uptake. Following incubation, cells were washed thoroughly
and incubated with proteinase K (2 mg/ml) for 1 h at 4°C to remove
membrane-bound phage. Proteinase K was quenched by PMSF (1 M)
and after a subsequent wash, the cells were lysed by freeze thawing
and the M13 content was determined through a colony assay (CFU).
Binding and uptake are expressed as percentage of the input CFU and
values represent means  variation of at least two experiments.
FIG. 4. Relative contributions of parenchymal cells (PC, filled bars)
and nonparenchymal cells (NPC, hatched bars) to the hepatic uptake of
lacM13 (in percentage of total recovered). 35S-lacM13 was injected in
mice at a dose of 1010 CFU per 200 l PBS. At 20 min after injection of
the radiolabel, parenchymal cells (PC, filled bars) and nonparenchymal
cells (endothelial and Kupffer cells, NPC, hatched bars) were isolated
from the liver, and the PC and NPC fraction were assayed for CFU and
35S radioactivity. Values are expressed as percentage of the total liver
uptake and represent means of three experiments  variation.
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sucM13 by liver and spleen to that of unmodified M13
(6% ID and 0.8% ID, respectively, data not shown), indi-
cating that hepatic and splenic uptake can be completely
prevented by blocking scavenger receptor-mediated up-
take and that nonspecific association of sucM13 to liver
and spleen is very low. To investigate the internalization
rate of sucM13 in vivo, sucHSA was injected at 4 and 19
min after injection of sucM13 and the plasma radioactiv-
ity was determined (Fig. 6). The amount of releasable
(and thus membrane-associated) sucM13, calculated by
correcting for control sucM13 serum levels, was 17% at 4
min after injection of 35S-sucM13, while at 19 min only 6%
of the tissue-associated radioactivity could be released.
This indicates that within 20 min virtually all of the tissue-
associated 35S-sucM13 was inaccessible to sucHSA and
probably internalized.
The low recovery of CFUs as compared to 35S-radio-
activity at 30 min after injection of unmodified M13 and
modified M13 in mice pointed to phage degradation after
uptake by the target tissue. The kinetics of degradation
of 35S-sucM13 after internalization were studied by com-
paring the recovery of phage-derived 35S-radioactivity at
the major elimination sites with that of infectious phage
(CFU) at 10, 30, 90, and 360 min after injection. During
this time span, the 35S-radioactivity remained constant in
all organs. The amount of CFUs, however, decreased
dramatically after a 10 min (liver, spleen, lungs) or 30
min (kidney, heart) lag phase. As a measure of phage
degradation in vivo, the recovery of infectious phage in
the various organs, calculated as a percentage of the
recovered radioactivity, is shown in Fig. 7. The method of
injection in Fig. 7 (tail vein injection instead of vena cava
injection) did not influence the outcome of the results.
Degradation was observed in all organs, but appeared to
be most pronounced in the liver. In fact, phage infectivity
in liver was reduced by a factor of 5000 within 90 min
after injection, 100-fold more active than the degradation
rate in the other organs.
DISCUSSION
So far, in vivo biopanning has been successfully ap-
plied for identifying peptides or antibodies targeting the
vascular endothelium of specific organs (Pasqualini and
Ruoslahti, 1996; Rajotte et al., 1998), atherosclerotic le-
sions (Houston et al., 2001), tracheal tumors (Kennel et
al., 2000), and thymic endothelium (Johns et al., 2000).
However, a quantitative biodistribution profile of (se-
lected) phage has never been assessed, mainly because
kinetic analysis was based on phage infectivity rather
than on the number of phage particles (Yip et al., 1999).
As internalization and degradation of selected phage
after receptor binding (Hart et al., 1994; Ivanenkov et al.,
1999b) might perturb the outcome and interpretation of in
vivo selections, the biodistribution profile of in vitro se-
lected phage (Koivunen et al., 1999), and the use of
phage as a gene delivery vehicle (Larocca et al., 1999;
Giovine et al., 2001; Monaci et al., 2001), we have ad-
dressed the uptake and processing of wild-type and
receptor-targeted phage in vivo.
To chase the fate of unmodified bacteriophage and
phage with high affinity for an internalizing receptor, we
metabolically labeled bacteriophage M13 with [35S]me-
thionine/cysteine. The 35S-radiolabeling enabled us to
quantify phage particle recovery from tissue in an acces-
sible, quick, and reproducible manner, with the advan-
tage that also noninfectious phage can be assessed.
This method will be particularly useful for the in vivo
determination of internalizing phage. In contrast, 125I-
radiolabeling of phage leads to nonspecific liver uptake
of nonviable phage (T. J. M. Molenaar et al., unpublished
results; Johns et al., 2000). Using 35S-radiolabeled phage,
we show that bacteriophage M13 is slowly cleared from
FIG. 7. Relative amount of sucM13 colony forming units (CFU) after
internalization by kidney (}), spleen (Œ), heart, (●), lungs (), and liver
(f). Mice were injected with 35S-sucM13 (1010 CFU in 200 l PBS) and
perfused with DMEM at 10, 30, 90, or 360 min after injection. The
organs were homogenised and assayed for 35S radioactivity and CFU
values. To indicate phage degradation, the ratio between CFU and dpm
values is calculated for the indicated organs.
FIG. 6. In vivo competition of sucM13 with sucHSA. 35S-sucM13 was
injected in mice at a dose of 1010 CFU in 200 l PBS. At 1 min before
(f) and 4 () and 19 min (Œ) after injection of sucM13 (arrows), sucHSA
(40 mg/kg in 200 l PBS) was injected by intravenous injection and
blood samples were taken at the indicated time points. Values repre-
sent means of duplicate experiments  variation.
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the circulation with a half-life of 4.5 h in C57Bl/6 mice
(around 4 h in 129/ICR white mice). Uptake was mainly by
spleen and liver, pointing at uptake by the reticuloendo-
thelial system (RES). The RES is mainly active in liver,
spleen, and lungs and contains a well-defined lysosomal
system that is specifically equipped to take up, kill, and
degrade invading microorganisms. Recovery of virulent
phage in organs such as lungs, liver, and spleen was
considerably lower (4–5) than that of 35S-radioactivity
already at 30 min after injection, pointing at substantial
disintegration of phages in these organs after uptake
and processing by the RES. In kidney and heart, inacti-
vation of M13 was not visible, suggesting that uptake in
these organs is by a nondegrading system or that the
phage recovered from heart and kidney are merely
trapped in capillaries.
This is the first time that a clear biodistribution profile
of bacteriophage M13 is presented in mice. That seems
surprising, because the use of M13 in vivo and in vitro
has tremendously increased over the last couple of
years, not only as a result of the many peptide and
antibody phage display selections, but also due to recent
advances in immunization experiments with phage-dis-
played peptides (Bastien et al., 1997; Frenkel et al., 2000;
Galfre et al., 1996; Grabowska et al., 2000; Meola et al.,
1995; Yu et al., 2000) and gene therapy using (recombi-
nant) bacteriophage M13 (Larocca et al., 1998, 1999;
Giovine et al., 2001). For example, knowledge on the fate
of wild-type M13 may be used to optimize the efficiency
of immunization studies.
To investigate the in vivo fate of receptor-targeted
phage, we chemically modified M13 by conjugation of a
specific ligand to the protein coating of M13. Several
chemical modifications to proteins have been described
to confer receptor-specific uptake of proteins. Lactosy-
lated low-density lipoprotein (LDL) is taken up by paren-
chymal cells and Kupffer cells in the rat liver (Bijster-
bosch and Van Berkel, 1990). In addition, anionic ligands
such as acetylated LDL or succinylated HSA are known
as specific ligands for scavenger receptors on macro-
phages and sinusoidal liver cells (Nagelkerke et al.,
1983; Kamps et al., 1997; Jansen et al., 1993b). Both
succinylation and lactosylation modify lysine residues.
Succinylation of M13 will lead to the introduction of
negative charges on the phage surface instead of the
positively charged lysines; lactosylation does not alter
the surface charge as the lysine can still be protonated
(Schwartz and Gray, 1977). Analogously, it is anticipated
that succinylated bacteriophage M13 will target scaven-
ger receptors on macrophages in liver and spleen, while
lactosylated M13 would enable us to investigate the
possible extravasation of M13 to subendothelial paren-
chymal cells. Indeed, lactosylated (lacM13) or succiny-
lated bacteriophage M13 (sucM13) display a completely
altered biodistribution profile than M13. LacM13 and
sucM13 are cleared from the circulation with half-lives of
18 and 1.5 min, respectively, reflecting the high affinity of
the ligands for the targeted receptors. Lactosylated M13
is taken up exclusively by the liver at 30 min after injec-
tion, while succinylated M13 can be recovered from both
liver and spleen. Apparently, scavenger receptors and
the galactose particle receptor are capable of rapid in-
ternalization of these large particles.
An important limitation to the phage display selections
in vivo is the fact that selections can only be accom-
plished for endothelial targets, as extravasation of phage
was suggested to be slow (Yip et al., 1999; Pasqualini
and Ruoslahti, 1996). In particular, phage which are
readily internalized in vitro might not be able to reach
their target in vivo at all. This is confirmed by the lacM13
biodistribution experiment. Although the size limit for the
ASGPr for spheric particles is 70 nm (Rensen et al.,
unpublished observations), the uptake of nonspheric
lacM13 by isolated parenchymal cells in vitro is rapid
and lactose specific. However, the parenchymal cells
appear to be quite inaccessible in vivo. The large size of
the phage (6 500 nm) suggests that phage are unlikely
to pass the fenestrae (100 nm in diameter) (Wisse et al.,
1985) and that hepatic uptake can be mainly attributed to
the galactose particle receptor on Kupffer cells. Never-
theless, 8% of the lactosylated M13 are still able to reach
the PCs, possibly due to their flexible, rod-like geometry.
These results confirm that extravasation of infectious
phage to subendothelial tissue does occur, albeit at a
slow rate. Therefore, when selecting for subendothelial
targets, the first rounds of selection (having only a few
copies per individual phage clone) should be accom-
plished in vitro, to enhance the copy number of the
phage, a strategy employed by Samoylova and Smith to
isolate muscle binding peptides (Samoylova and Smith,
1999).
A second hurdle which might be encountered in in vivo
biopanning is the loss of infectivity due to lysosomal
degradation after uptake. The infectivity of lactosylated
M13, succinylated M13, and unmodified M13 in the in-
ternalizing organs was reduced by 45–73% within the
first 30 min after injection. For sucM13, phage internal-
ization proceeds very rapidly: within 20 min after injec-
tion, 95% of the liver-associated sucM13 is inaccessi-
ble to sucHSA competition. Interestingly, degradation of
sucM13 is only observed after a minimal lag time of 10
min (liver, spleen, lungs) or 30 min (kidney, heart). This
lag time probably reflects intracellular transport of the
phage to subcellular compartments and subsequent
degradation. Uptake by scavenger receptors proceeds
via a lysosomal route, and the processing of internalized
macromolecules is very fast (10 min), especially in the
liver macrophages. These kinetic studies on phage in-
ternalization in vivo imply that for in vivo phage selection,
the circulation time must generally not exceed 10 min.
Due to premature degradation of internalized phage, the
first round of selection is particularly critical, because
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often 100 copies are present per individual phage
clone. The rapid degradation of internalized phage also
stresses the importance of radiolabeling for quantitative
assessment of selected phage as CFU values will pro-
vide considerable underestimation of real uptake.
A third implication of this study is that phage can be
redirected to specific cell types in vivo by chemical
modification with high-affinity ligands for cell-specific
receptors. It has already been shown in vitro that gene
transfer can be established by using chemically (Larocca
et al., 1998) or genetically (Larocca et al., 1999; Giovine et
al., 2001) targeted phage. Peptides isolated via phage
display have been used to retarget adenovirus gene
delivery to airway epithelial cells (Romanczuk et al.,
1999) and endothelial cells (Nicklin et al., 2000). Chemi-
cal modification of M13 phage did not affect the integrity
and infectivity of the phage, while considerably altering
its biodistribution profile and its ability to enter specific
cell types. In this respect, chemical modification may be
an accessible strategy to improve efficacy and specificity
of phage. A major advantage of bacteriophage M13 in
gene delivery strategies as compared to adenoviral vec-
tors might be its very low nonspecific uptake. However,
the slow extravasation of phage into the subendothelial
tissue suggests that the use of bacteriophage as gene
delivery vectors might be restricted to the endothelium.
Apart from gene delivery using recombinant phage, the
retargeting of M13 might also be used for other pur-
poses. Immunization of organisms using phage-dis-
played peptides (Bastien et al., 1997; Frenkel et al., 2000;
Galfre et al., 1996; Grabowska et al., 2000; Meola et al.,
1995; Yu et al., 2000) requires the uptake of M13 by
antigen-presenting cells, including macrophages and
dendritic cells. Succinylation of phage induces macro-
phage uptake, mainly through SR-A, and may thus be
beneficial for antigen presentation by macrophages.
Dendritic cells express scavenger receptors such as
CD36 and CD68 (Matasic et al., 1999). CD36 has a
similar binding pattern as SR-A and is able to internalize
polyanionic particles (Yamada et al., 1998; Terpstra et al.,
2000), and dendritic cells are therefore expected to take
up succinylated, polyanionic, phage. We anticipate that
the induced uptake of recombinant succinylated phage
by macrophages and, probably, dendritic cells, leads to
an improved immunization of phage displayed peptides
or antibodies.
In conclusion, we show that 35S-radiolabeled phage
enables a more accurate quantification of the biodistri-
bution profile and pharmacokinetics of wild-type and
selected phage than by using infectivity assays, that
targeted phage are rapidly internalized and degraded in
vivo within 30–90 min after injection, and that extravasa-
tion of phage does occur, albeit at a very low rate. This
has important implications for future in vivo selection
protocols, for assessing the effectiveness of in vitro or in
vivo selected phage, and for the potential use of phage
as a viral gene-transfer vehicle.
MATERIALS AND METHODS
Materials
The phagemid pComb8 library, containing a CX15C
insert, was a generous gift from H. Pannekoek, Amster-
dam Medical Center, University of Amsterdam, The Neth-
erlands. Succinic anhydride was from Janssen Chimica,
Geel, Belgium. MOPS was from Boehringer Mannheim,
Mannheim, Germany. Thiamine and BSA (fraction V)
were obtained from Sigma, St. Louis, MO. D-Lactose and
PMSF were supplied by Merck, Darmstadt, Germany.
Sodium cyanoborohydride was from Aldrich, Brussels,
Belgium. VCSM13 was from Stratagene, La Jolla, CA.
Solvable was obtained from Packard, Meriden, USA. The
SMART system, Sephacryl S1000 column, and the
[35S]methionine/cysteine promix were from Amersham-
Pharmacia Biotech, Little Chalfort, U.K. The Mini Bead
Beater was obtained from Biospec, Bartlesville, USA.
Mice
Wild-type C57Bl/6KH mice and 129/ICR white mice
were obtained from Jackson Laboratories (Bar Harbor,
ME) and bred in our local facility under specific patho-
gen-free conditions. All experiments were approved by
the medical ethical committee on animal experiments of
the Leiden University.
Determination of colony forming units
F Escherichia coli (XL1-blue) was grown at 37°C to
mid-log-phase in super broth media (30 g/l tryptone, 20
g/l yeast, 10 g/l MOPS), OD600  0.5–0.8. M13 bacterio-
phage library pComb8, containing an ampicillin-resis-
tance gene, was diluted in phosphate-buffered saline
(PBS) to an estimated amount of 100 infectious phage
particles per 10 l PBS and allowed to infect 100 l of
XL1-blue (10, 37°C). Infected bacteria were plated on
ampicillin-containing agar plates, incubated o/n at 37°C,
and colonies (CFUs) were counted the next day.
Radiolabeling of bacteriophage M13
XL1-blue bacteria were infected with M13 and grown
to OD600 	 0.2. After infection of the bacteria with helper
phage VCSM13 for 30 min, the bacteria were centrifuged
and dissolved in M9 minimal medium (Sambrook et al.,
1989) supplemented with ampicillin (10 g/ml), kanamy-
cin (50 g/ml), thiamine (1 g/ml), and [35S]methionine/
cysteine promix (10 Ci/ml). Cultures were grown over-
night at 37°C with shaking. Bacteria were pelleted by
centrifugation and the metabolically labeled phage were
precipitated from the supernatant by the addition of 1/5
vol 20% PEG6000/2.5 M NaCl and dissolved in PBS
containing 0.2% sodium azide. Free 35S was removed by
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repetitive precipitation of the phage until the pellet con-
tained 97% of total radioactivity. The specific activity of
35S-M13 phage was 10
6–10
5 dpm/CFU.
Succinylation and lactosylation of M13
Succinylated-M13 (sucM13) was prepared by adding 2
l succinic anhydride (50 mg/ml in DMSO) to 100 l M13
(1012 CFU in 0.2 M K2HPO4, pH 8.0) and gently stirring the
solution for 1 h at 4°C. Studies on succinylated human
serum albumin, bovine serum albumin (BSA), and low-
density lipoprotein have shown 60–100% succinylation of
lysine residues after 1 h incubation (Jansen et al., 1993b;
Swart et al., 1999; Haberland et al., 1984).
To prepare lactosylated M13 (lacM13), bacteriophage
M13 (1010 CFU/l in 20 mM sodium phosphate buffer, pH
7.0) was incubated at room temperature with lactose and
sodium cyanoborohydride to final concentrations of 100
and 50 mg/ml, respectively. After 5 h, the reaction was
quenched by adding 10 vol 0.1 M glycine and dialyzed
exhaustively against PBS. The degree of lactosylation of
M13 was determined using [14C]lactose. After 5 h, ap-
proximately 25% of the maximal binding by lysine resi-
dues (1 pmol/g protein) was observed (not shown). The
recoveries of phage titers (CFU) after succinylation and
lactosylation of the phage varied between 80 and 100%.
Gel filtration analysis of sucM13 and lacM13
M13, lacM13, or sucM13 (109 CFU in 50 l PBS) was
injected onto a SMART system, using a Sephacryl S-1000
SF column equipped with a 50-l sample loop, and
eluted at a flow rate of 50 l/min with PBS (pH 7.4).
Fractions (50 l) were collected and assayed for both
35S-radioactivity and CFU.
In vivo serum clearance and tissue distribution
For short time-span studies (30 min), mice (male,
25–30 g) were anesthetized, the abdomen opened, and
35S-labeled M13 samples were injected in the vena cava
inferior. For long-time spanning studies (1.5 and 6 h),
injection was performed via the tail vein. At the indicated
time points, blood samples were taken and allowed to
clot for 30 min. The serum, obtained after centrifugation
for 1 min at 16,000 g, was assayed for 35S-radioactivity
and CFUs. The half-lives of the injected phage were
calculated with GraphPad Prism 3.0 (ISIS Software, Mot-
ulsky). After the last time point, mice were perfused with
DMEM (RT, 100 mmHg) for 2 min at 10 ml/min via a
cannula in the left ventricle of the heart, and organs were
removed, weighed, and snap-frozen in liquid nitrogen.
Organs were homogenized in 1 ml 0.1 M HCl pH 2.2 with
1 mm glass beads using a Mini Bead Beater and the
amount of CFU in the organ was determined by infecting
E. coli with diluted organ homogenate. The remaining
fraction was dissolved in Solvable and assayed for 35S-
radioactivity.
Contribution of liver cell types to hepatic uptake
Mice were anesthetized and injected with 35S-labeled
lacM13 as described in the previous section. At 20 min
after injection, the abdomen was opened, the vena cava
was cannulated via the right ventricle of the heart, and
the liver was perfused with Ca2 free Hank’s balanced
salt solution containing 10 mM HEPES, pH 7.4 at 14
ml/min. After 10 min a liver lobule was tied off for deter-
mination of the total liver uptake. The liver was subse-
quently perfused with 0.05% (w/v) collagenase in Hank’s
medium containing 10 mM HEPES, pH 7.4, and paren-
chymal cells and nonparenchymal cells were isolated as
described previously (van Berkel et al., 1985). Purity of
the cells was assessed by phase-contrast microscopy,
PCs being much larger than NPCs. Purity was 95%,
contamination of NPC in PC fraction was 1%.
PC and NPC fractions were assayed for 35S and CFUs.
The contribution of the various cell types to the total liver
uptake was calculated as described previously
(Nagelkerke et al., 1983). Protein concentrations of the
PC and NPC fraction were determined by the method of
Lowry et al. (1951), with bovine serum albumine as stan-
dard.
In vitro uptake of lacM13 to parenchymal liver cells
Primary mouse parenchymal cells were isolated es-
sentially as described above. Cells were washed twice
with DMEM/2% BSA and the viability (80%) was
checked with 1.4 mg/ml trypan blue. Cells (106 cells/ml)
were incubated with lacM13 (1011 CFU/ml) at 37°C under
a carbogen atmosphere with constant agitation (150
rpm). Incubations with nonlactosylated phage at 37°C
and incubations with lactosylated phage at 4°C were
used as negative controls. After 2 h, cells were washed
with ice-cold DMEM and incubated with DMEM/protein-
ase K (2 mg/ml) for 1 h to remove extracellular phage.
Proteinase K was inactivated by the addition of 1 M
PMSF at 4°C and cells were lysed by freeze thawing.
Samples were assayed for CFUs.
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